ARTICLE | Emerging Company Profile

Kira: depleting activated dendritic cells

Kira aims to deplete activated dendritic cells for GvHD and autoimmune disease

March 7, 2020 12:05 AM UTC
Updated on Mar 7, 2020 at 1:07 AM UTC

First-in-class mAbs against activated dendritic cells from Australian newco Kira could block the inflammation and immune response associated with GvHD and autoimmune diseases without the risk of infection that accompanies broad immunosuppression.

Founding CEO Dan Baker told BioCentury Kira Biotech Pty. Ltd. has rights to its lead antibody KB312 and a backup antibody from DendroCyte BioTech Pty. Ltd...